Introduction {#Sec1}
============

Increasing incidences of poor vision and ocular diseases have been described in Alzheimer's disease (AD) patients (Bayer et al. [@CR8]). AD-related visual dysfunction can be attributed to any defects occurring in the visual pathway, including damage in visual cortical areas and degeneration of pre-cortical areas (Guo et al. [@CR36]). Glaucoma and age-related macular degeneration (AMD) are the frequently occurring ocular diseases associated with AD (Blanks et al. [@CR10]). Recently, many laboratories have taken efforts to investigate the link of retinal degeneration and AD. Retinal abnormalities such as extensive loss of retinal ganglion cell (RGC) (Mendez et al. [@CR64]; Blanks et al. [@CR10]), reduced thickness of retinal nerve fiber layer (NFL) (Hedges et al. [@CR38]), and reduced retinal blood flow (Guo et al. [@CR36]) are observed in AD patients.

Owing to the limitations on the investigations of AD in human postmortem studies, transgenic AD mouse models have been used to mimic the human pathological environment. AD mice are engineered to express human mutant genes found in early-onset AD patients. The majority (30--40%) of familial Alzheimer's disease (FAD) is resulting from autosomal dominant inheritance with mutated genes encoding presenilin 1 (PS1) on the long arm of chromosome 14, presenilin 2 (PS2) on chromosome 1, and amyloid precursor protein (APP) on chromosome 21 (Price et al. [@CR83]). Several lines of transgenic mice bearing the abovementioned gene mutations were shown to exhibit some neuropathological features of human AD (Eriksen and Janus [@CR25]). Many researchers have been taking these transgenic mice as experimental models to study AD-related retinal degeneration.

This review focuses on the current knowledge obtained from AD transgenic mouse models. First, it begins with their genetic backgrounds. Then, it summarizes AD-related pathologies in their brains. Finally, the review goes through the retinal changes in these mice. It is our attempt to stimulate researches in AD-related retinal degeneration, which will have a significant impact in pathologies and therapeutics in both AD and retinal degeneration such as glaucoma and AMD.

Transgenic mouse models {#Sec2}
=======================

To study the AD pathogenesis in the brain, AD transgenic mice have been widely investigated. Different types of transgenic mice may be complementary to the disadvantages of each other as experimental models of AD. For example, transgenic mice expressing mutant genes encoding APP and PS1 can be used to evaluate the process of amyloidogenesis at the pre-dementia phase of AD as the accumulation of Aβ deposits or even plaques in the brain tissues and the retinas are observed in these transgenic lines (Zahs and Ashe [@CR113]). The pathology of another lesion, tau, can be elucidated by studying tau mutant mice in which hyperphosphorylated tau and NFT are expressed (Frank et al. [@CR26]). Taking these research reports together, it is possible to use different types of transgenic mouse models, which would compensate the shortcomings of each other, to study AD in a multifactorial way.

Among various models, our review focuses on mutated APP mouse models, mutated APP/PS1 mouse models, mutated tau mouse models, and triple transgenic mouse (3xTg) model (listed in Table [1](#Tab1){ref-type="table"}). The expression of AD mutations is based on three criteria: the host strains, the choice of promoter, and the extent of gene expression. Table 1Pathological features of AD transgenic mouse modelsNamePromoterMutant genesPathological featuresClinical featuresReferenceAPP~V717I~Thy-1HuAPP695.V717IHigher secretion of Aβ42Spatial and non-spatial orientation deficits; memory impairment; long-term potentiation impairmentPrice and Sisodia [@CR81]; Pezzini et al. [@CR79]; Tanghe et al. [@CR98]APP~swe~Hamster PrPHuAPP695.K670N-M671LOnset of AD varied from 3 to 15 months of age; associated with age-dependent oligomeric AβMemory loss at 6 months of ageHsiao et al. [@CR43]; King et al. [@CR50]; Morgan et al. [@CR67]; Kawarabayashi et al. [@CR49]; Westerman et al. [@CR106]; Duyckaerts et al. [@CR24]APP~swe~/APP~V717I~Thy-1HuAPP695.V717I; HuAPP695.K670N-M671LDeposition of Aβ, Aβ plaques, and hyperphosphorylated tauLocomotor activity decreasedPrice et al. [@CR82]; Le Cudennec et al. [@CR55]APP~swe~/PS1~∆E9~Murine PrPHuAPP695.K670N-M671L; in-frame deletion of exon 9 of PS1 geneOnset of AD at 4--5 months of age; elevated secretion levels of Aβ peptides; accumulation of senile Aβ plaquesAssociative and spatial memory impairmentPrice and Sisodia [@CR81]; Price et al. [@CR83]; Duyckaerts et al. [@CR24]; Gruart et al. [@CR33]APP~SL~/PS1~M146L~Thy-1HuAPP695.V717I; HuAPP695.K670N-M671L; PS1.M146LIntracellular accumulation of Aβ occurred at 2 months of age; Aβ plaques appeared at 3 months of ageN.A.Casas et al. [@CR13]; Bayer and Wirths [@CR7]Tau~P301L~Murine PrP/Thy-1FTPD-17. P301LAccumulation of NFT in brain tissues and spinal cordSpatial cognitive impairmentGarcia et al. [@CR27]; Spires and Hyman [@CR93]; Eriksen and Janus [@CR25]; Frank et al. [@CR26]Tau~P301S~Thy-1.2FTPD-17.P301SLocalization of hyperphosphorylated tau in the brain and spinal cordImpairment of motor coordinationAllen et al. [@CR1]; Frank et al. [@CR26]; Scattoni et al. [@CR90]3xTgThy-1.2HuAPP695.K670N-M671LOnset of AD at 3 months of age; progressive accumulation of plaques and tanglesLong-term potentiation impairmentCaroni [@CR12]; Oddo et al. [@CR75]PS1.M146VFTPD-17.P301L*N.A.* not applicable, *Swe* Swedish mutation, *3xTg APP*~*swe*~*/PS1*~*M146V*~*/Tau*~*P301L*~ triple transgenic mice

APP mutant-related transgenic mice {#Sec3}
----------------------------------

APP~V717I~ transgenic mice, also named as "London" mutation, were the first FAD mutant mice dated back to 1993 (Price et al. [@CR83]). The mutant APP gene expressed under Thy-1 promoter harbors the substitution of Val residue at position 717 near the γ-secretase cleavage site (Price et al. [@CR83]). Cells with APP mutations of Val717 were accompanied by a higher secretion of Aβ42 compared to cells with wild-type APP (Price and Sisodia [@CR81]; Pezzini et al. [@CR79]).

Another widely used APP mutant model known as "Swedish mutation" was subsequently developed by Karen Hsiao Ashe in 1996 (Hsiao et al. [@CR43]). It is based on the finding that the human APP695 double mutation form (Lys670→Asn and Met671→Leu) with the Kunitz-like proteinase inhibitor domain was absent in the early-onset AD Swedish family (Dutescu et al. [@CR23]). The construct is inserted into a hamster prion protein (PrP) cosmid vector with the PrP open reading frame replaced by variant APP. The mice carrying the gene above are named as Tg (HuAPP695.K670N-M671L) 2576 (Hsiao et al. [@CR43]). The onset of AD is varied among studies in Tg2576 mice, ranging from the earliest at 3 months of age to the latest at 15 months of age (Hsiao et al. [@CR43]; King et al. [@CR50]; Morgan et al. [@CR67]; Kawarabayashi et al. [@CR49]). Despite the varying onset of AD, APP~swe~ mice are often associated with age-dependent oligomeric Aβ accumulation (Duyckaerts et al. [@CR24]).

APP~swe~/APP~V717I~ co-expressed transgenic mice are also made available to recapitulate the neuropathological alteration occurring in AD (Le Cudennec et al. [@CR55]). These two lines of transgenic mice, driven by the Thy-1 promoter, show deposition of Aβ or even plaques and hyperphosphorylated tau, depending on the extent of transgene expression (Price et al. [@CR82]).

PS mutant-related transgenic mice {#Sec4}
---------------------------------

Mutation of APP accounts for the minority cases of early-onset FAD; the majority pedigrees of AD come from the mutation of PS1 or PS2 (Spires and Hyman [@CR93]). To date, a number of mutant PS variants were developed such as ∆E9, M146L, A246E, L286V, L392V, and H163R from PS1 mutation and N141I from PS2 mutation (Price and Sisodia [@CR81]). Therefore, mutation of PS1 or PS2 alone is not sufficient to mimic the pathologies of FAD. Although Aβ42 was over-produced in these single mutant mice (Duyckaerts et al. [@CR24]), the hallmark lesions of AD including either Aβ plaques or neurofibrillary tangles (NFT) were not observed in brain tissues (Price and Sisodia [@CR81]; Spires and Hyman [@CR93]; Duyckaerts et al. [@CR24]).

APP/PS1 double-transgenic mice {#Sec5}
------------------------------

Crossing APP mutant genes with PS1 mutant genes seems to be a reasonable alternative way to elicit amyloid pathology. Increasing opportunities of amyloidogenesis from APP can accelerate the pathogenesis of AD (Spires and Hyman [@CR93]). Indeed various transgenic mice expressing different kinds of mutated PS1 and mutated APP genes were generated in which different levels of Aβ expressions were observed.

One example of double-transgenic mice (2xTg) is APP~swe~/PS1~∆E9~, which carries both APP Swedish mutation and human PS1 gene with an in-frame deletion of exon 9 (Price and Sisodia [@CR81]; Price et al. [@CR82]). The exon 9 deletion in PS1 could elevate the secretion levels of Aβ peptides; large and homogeneous senile plaques accumulated in the human brain (Duyckaerts et al. [@CR24]). This type of mice generated Aβ plaques at the early age of 4--5 months of age (Duyckaerts et al. [@CR24]).

Another 2xTg mouse model, APP~SL~/PS1~M146L~, carries both Swedish and London mutation (K670N/M1671L and V717I) in human APP 751 gene together with a human mutant gene PS1~M146L~ (Casas et al. [@CR13]; Bayer and Wirths [@CR7]). Aβ plaques appear at 3 months of age and the intracellular accumulation of Aβ occurred as early as 2 months (Bayer and Wirths [@CR7]).

The APP single Tg mice or APP/PS1 2xTg mouse models have replicated the amyloidogenic events in AD. This makes them valuable in the study of amyloid pathologies in the brain. For example, APP V717I transgenic mouse model has been used to study early behavioral and cognitive deficits accompanied by over-expression of APP (Moechars et al. [@CR66]). Tg2576 mouse line has been implicated in the investigation of accelerate amyloidogenesis such as phosphorylated elf-2α (O'Connor et al. [@CR74]). The downstream pathological events of Aβ deposits such as inflammation have been studied by using APP~SL~/PS1~M146L~ mutant mice as an experimental model (Jimenez et al. [@CR46]). All of these transgenic models have been employed for investigating enzymatic activities of the amyloidogenic pathway, the better understanding of which is conducive to the development of drugs such as β-secretase (BACE1) inhibitors that could attenuate amyloidogenesis (Gau et al. [@CR31]; Malamas et al. [@CR60]). Amyloid pathology can therefore be studied in great detail with AD amyloidogenic mice.

Tau mutant-related transgenic mice {#Sec6}
----------------------------------

Extant amyloidogenic AD models do not express the full spectrum of neuropathology in AD but elicit only plaques without NFT (Oddo et al. [@CR75]). To supplement that, tau mutant mice have been used to study AD, frontotemporal lobe dementia, or other tauopathies. Tau mutation occurs on chromosome 17 (Frank et al. [@CR26]). Tau mutant mice can express hyperphosphorylated tau and even NFT in the brain (Price et al. [@CR82]). One type of tau-mutated gene expresses Leu instead of Pro at the position of 301 (P301L) in both the shortest (driven by mouse prion promoter, JNPL3 line) and longest (driven by mouse Thy-1 promoter) four-repeat tau isoforms, producing NFT in brain tissues and spinal cord (Spires and Hyman [@CR93]; Eriksen and Janus [@CR25]). This mouse line has been studied to find out the correlation between frontotemporal lobe dementia and tauopathy as well as the mediation of cognitive impairment associated with axonopathy (Terwel et al. [@CR99]; Frank et al. [@CR26]). Another type of tau mutant (P301S) involves the substitution of Ser instead of Pro on exon 10 of chromosome 17 driven by Thy-1.2 promoter (Frank et al. [@CR26]). Hyperphosphorylated tau was also detected extensively in the brain and spinal cord (Allen et al. [@CR1]).

APP~swe~/PS1 ~M146V~/Tau~P301L~ triple transgenic mice (3xTg) {#Sec7}
-------------------------------------------------------------

The transgenic mice harbor mutation of human APP~swe~, PS1~M146V~, and Tau~P301L~. Tg2576 mice with the use of Swedish double mutation of human APP695 and four-repeat tau (4R0N) without amino terminal inserts are inserted into exon 3 with the drive of Thy-1.2 expression cassette cDNA. These constructs are then co-microinjected into mutant homozygous PS1~M146V~ knock-in mice (Oddo et al. [@CR75]). The manipulation of co-integration of APP and tau transgene at the same site with the PS1~M146V~ knock-in can establish a stable source of 3xTg mice. In addition, Thy1.2 expression cassette is used to ensure transgenes to express predominantly in the CNS (Caroni [@CR12]). This type of transgenic mice is regarded as a good model recapitulating AD pathology. The onset of AD pathology occurs at 3 months of age (Spires and Hyman [@CR93]). Impairment of long-term potentiation was observed. Plaques and tangles were progressively developed in an age- and region-dependent manner. The pathological changes also support the amyloid cascade hypothesis in which amyloid pathology precedes tauopathy shown in an anti-Aβ antibody immunization test (Oddo et al. [@CR75]). In addition, studies found that Aβ, especially the intracellular Aβ42, was in correlation with intracellular NFT in the AD brain via tau hyperphosphorylation pathways (Grundke-Iqbal et al. [@CR34]; Hardy and Selkoe [@CR37]).

Retinal degeneration in AD transgenic models {#Sec8}
============================================

Reports of visual deficits in AD patients dated back to 20 years ago. Behavioral studies on AD transgenic mice showed that the mice suffered from visual dysfunction (Arendash et al. [@CR4]). Emerging evidence has been attempting to reinforce the potential link between retinal degeneration and AD (Dutescu et al. [@CR23]). Hypothetically, the over-expression of APP, the production of soluble Aβ, and Aβ deposition will lead to the formation of amyloid plaques which can induce cell death via the apoptotic pathway (Wostyn et al. [@CR107]). Furthermore, Aβ plays a role in inducing the hyperphosphorylation of tau, which in turn induces changes of the integrity of retinal cells and their synapses in the INL (Muyllaert et al. [@CR69]). It has been reported that the over-expression of APP, Aβ and/or tau deposition, neuronal cell loss, retinal glial cell changes, and vascular changes occur in the retina of AD transgenic mice. The retinal histopathology changes in the AD transgenic mouse models are summarized in Table [2](#Tab2){ref-type="table"} and demonstrated in a schematic diagram in Fig. [1](#Fig1){ref-type="fig"}. Table 2Retinal histopathologic changes in AD transgenic mouse modelsNamePromoterMutant genesAPP over- expressionAβ depositsP-tau depositsNeuronal cell loss\^Aβ-deposited vasculatureReference2- to 18-month-old Tg2576Hamster PrPHuAPP695.K595N, M596L+++±N.A.N.A.YesDutescu et al. [@CR23](GCL, INL)(GCL, RV)14-month-old Tg2576N.A.HuAPP695.K670N-M671L++++++±YesYesLiu, et al. [@CR58](GCL, INL)(GCL, IPL, INL, OPL, ONL, RV)(GCL,IPL, INL, OPL, ONL)+(OS)6- to 12-month-old Tg APP/PS1Murine PrpAPP~swe~, PS1~∆E9~++±N.A.N.A.YesDutescu et al. [@CR23](IPL, OPL)(GCL, INL, RV)10.5-month-old Tg APP/PS1Murine PrpAPP~swe~, PS1~∆E9~+++±N.A.YesYesNing et al. [@CR72](GCL)(NFL, CV)12- to 19-month-old APPSwe TgC3-3/PS1Murine PrpAPP~swe~, PS1~∆E9~N.A.(IPL, OPL)^a^N.A.NoN.A.Perez et al. [@CR78]7.8-month-old Tg 2576 x Tg1Hamster PrP, PDGFAPP~swe~, PS1~M146L~+N.A.YesYesNing et al. [@CR72](GCL, INL)27-month-old Tg 2576 x Tg1Hamster PrP, PDGFAPP~swe~, PS1~M146L~++++++N.A.YesYesNing et al. [@CR72](NFL, GCL, IPL, INL, OPL, OS, RPE, RV)(NFL, GCL)+(RV, CV)1- to 6-month-old homozygous Tau P301SMurine Thy-1Tau~P301S~N.A.N.A.±(IPL), with paired helical filament formationNoN.A.Gasparini et al. [@CR30]10- to 22-month-old 3xTgThy-1.2PS1~M146V~, APP~swe~, and Tau~P301L~N.A.Yes^a^N.A.YesN.A.Liu et al. [@CR58](layers not specified)*N.A.* not applicable, *swe* Sedish mutation, *P-tau* hyperphosphorylated tau, *\^* neuronal cells in the inner retinal regions, including INL and GCL, *NFL* nerve fiber layer, *GCL* ganglion cell layer, *IPL* inner plexiform layer, *INL* inner nuclear layer, *OPL* outer plexiform layer, *ONL* outer nuclear layer, *OS* outer segment, *RPE* retinal pigment epithelium, *RV* retinal vasculature, *CV* choroidal vasculature, *+++* strong level, *++* moderate level, *+* weak level, *+/−* present^a^Plaques formationFig. 1Diagram demonstrating APP expression, Aβ deposits in retinal layers of various kinds of AD transgenic mice. The background is a resin cross-section demonstrating a layered structure of retina. *Filled color shapes* are positioned quantitatively based on the expression levels of deposits. *Unfilled color shapes* show the presence of specific deposits only but not in quantitative manner. *NFL* nerve fiber layer, *GCL* ganglion cell layer, *IPL* inner plexiform layer, *INL* inner nuclear layer, *OPL* outer plexiform layer, *ONL* outer nuclear layer, *OS* outer segment, *RPE* retinal pigment epithelium

Over-expression of APP in the retina {#Sec9}
------------------------------------

Compared to the wild-type mice, a significant increase in the immunoreactivity of APP in the cytoplasm of the cells was detected in RGCL and INL of various transgenic mice (APP transgenic mouse (Tg 2576), APP~swe~/PS1~M146L~ and APP~swe~/PS1~∆E9~ double-transgenic mouse) (Ning et al. [@CR72]; Dutescu et al. [@CR23]; Liu et al. [@CR58]; Perez et al. [@CR78]). This over-expression of APP was age dependent as shown in APP~swe~/PS1~M146L~ transgenic mice. At 27 months old, a strong immunoreactivity of APP was detected not only in the different layers of retina such as, NFL, RGCL, IPL, INL, OPL, OS, and RPE but also in the retinal vasculature (Ning et al. [@CR72]).

Deposition of Aβ in the retina and retinal vasculature {#Sec10}
------------------------------------------------------

The deposition of Aß, derived from abnormal processing of APP, was found in the retinas of AD transgenic mice. In Tg2576 mice, Aβ was found to deposit from RGCL to INL or even at the outer nuclear layer (ONL) (Dutescu et al. [@CR23]; Liu et al. [@CR58]). In APP~swe~/PS1~∆E9~ transgenic mice, Aβ deposits usually accumulate in NFL, RGCL, and INL (Ning et al. [@CR72]; Dutescu et al. [@CR23]). Aβ plaques were found in plexiform layers; the size and the number of plaques significantly increased with age (Perez et al. [@CR78]).

Robust Aβ signal was detected around microvessels in RGCL of Tg2576 mice (Dutescu et al. [@CR23]; Liu et al. [@CR58]). Both the retinal and choroidal vascular Aβ deposits were reported in old-aged APP~swe~/PS1~M146L~ transgenic mice and middle-aged APP~swe~/PS1~∆E9~ (Ning et al. [@CR72]).

Deposition of hyperphosphorylated tau in the retina {#Sec11}
---------------------------------------------------

Hyperphosphorylated tau was detected and found to be associated with Aβ depositions in various retinal layers including RGCL, IPL, INL, OPL, and ONL in Tg2576 mice (Liu et al. [@CR58]). In homozygous P301S transgenic mice, hyperphosphorylated tau deposited in the NFL and aggregated into filamentous inclusions in RGCs starting from 2 months old (Gasparini et al. [@CR30]). The hyperphosphorylated tau and tau inclusions were found in cultured retinal explants from transgenic mice at the age of 5 months (Gasparini et al. [@CR30]).

Loss of retinal neurons in AD transgenic mice {#Sec12}
---------------------------------------------

Neuronal cell loss was reported in multiple AD transgenic lines. Apoptotic cells as shown by TUNEL staining were detected in RGCL of APP~swe~/PS1~M146L~ and APP~swe~/PS1~∆E9~ transgenic mice (Ning et al. [@CR72]). A significant reduction in the retinal thickness measured from the RGCL to ONL was detected in Tg2576 mice compared with non-transgenic control (Liu et al. [@CR58]). This indicates that there was a loss of either the photoreceptor cells at the ONL (rod and cone cells) or neuronal cells at the inner retinal layers (RGC, horizontal cells, bipolar cells, or amacrine cells).

Glial reaction in AD retina {#Sec13}
---------------------------

Glial reactions in the retina were detected in different kinds of AD transgenic mice at various ages. In APP~swe~/PS1~M146L~ transgenic mice, microglia was increased in an age-dependent manner, which was in parallel with Aß deposits and TUNEL-positive RGC in the GCL. The average percentage of cells in the GCL surrounded by microglial cells increased significantly from 10% in 7.8-month-old to 50% in 27-month-old APP~swe~/PS1~M146L~ transgenic mice (Ning et al. [@CR72]). In Tg2576 transgenic mice, a significant infiltration of microglial cells in the inner retina was detected as early as 4 months of age (Liu et al. [@CR58]). Qualitative evaluation revealed greater microglia immunoreactivity in the 12- to 19-month-old APP~swe~/PS1~∆E9~ transgenic mice when compared to age-matched non-transgenic control (Perez et al. [@CR78]). Increased microglia reaction demonstrated by an increase of GFAP immunoreactivity was also reported in the Tg2576 transgenic mice (Liu et al. [@CR58]).

The retina as a window of the brain {#Sec14}
===================================

Anatomy of the retina {#Sec15}
---------------------

Being a part of the central nervous system (CNS), the retina contains a high density of neuronal cells with a laminar structure outside the brain. There are six major types of neuronal cells distributed throughout the retina. Rods and cones are photoreceptors cells restricted to the outer segment of the retina. Horizontal cells, bipolar cells, and amacrine cells are located at the INL. The latter cell type may appear at the RGCL where RGCs are accumulated. During the visual process, light is detected by photoreceptor cells. The signals will then be relayed by the cells in the INL to RGCs. The nerve fibers of RGCs converge into the optic nerve fibers where signals are further transmitted to the visual cortex for visual processing. RGCs hold the responsibility of conducting the signal to the brain. The vulnerability of RGCs to stress factors such as inflammatory factors, high intracellular calcium ions, glutamate, or free radicals, or high intraocular pressures may lead to irreversible blindness.

Importance of studying the retina in AD {#Sec16}
---------------------------------------

As human life span is extended into old age, the prevalence of AD often increases along with the aging process. It is estimated that over 100 million people will suffer from AD by 2050 (Ron et al. [@CR86]). Visual impairment is associated with the prevalence of AD (Rizzo et al. [@CR84]; Berisha et al. [@CR9]; Valenti [@CR100]). For example, in a glaucoma study, the percentage of AD patients having glaucoma is 2.5 times higher when compared to that of normal patients (Tamura et al. [@CR97]). A rapidly increasing list of AD cases emphasizes an urgent need for a fair and promising research into the prevention of AD as well as the associated retinal diseases.

To our knowledge, it is still difficult to monitor the progressive degeneration of the brain with a fast, non-invasive, and less expensive method. The current diagnostic tools of the brain have limitations in terms of specificity of bio-markers and signal resolution (Klunk et al. [@CR51]; Koronyo-Hamaoui et al. [@CR53]). Thus, many attempts have been made to investigate AD with an easier approach by studying the retina. The laminar nature of retina can simplify the whole AD pathological investigation. Although there are ten layers in the retina, the retinal neurons are only located in three layers. Any abnormalities occurring in these three layers may have some pathological indications to the brain. For example, thinning of the inner retinal layer (from NFL, GCL to INL) indicates the loss of RGCs, horizontal cells, bipolar cells, or amacrine cells. A further examination of the specific neuronal cells in different layers may elucidate the pathological mechanisms induced by Aß efficiently. In addition, the retina can serve as an excellent alternative system for AD research because it can faithfully reflect the changes in the brain and offers unique advantages that can simplify the investigation of AD (Koronyo-Hamaoui et al. [@CR53]). Multiple lines of AD transgenic mice have elicited AD-like pathological hallmarks in the retina as disease progresses. Studying retinal degeneration with the use of AD transgenic mice can be a simple gateway for investigators to look into the AD pathological changes in the more complicated brain system. Evaluating the retina thus opens up a new avenue of AD research (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Schematic diagram suggests the importance of AD-related retinal degenerative research. The progressive degeneration of the brain may be associated with retinal diseases such as glaucoma and AMD. The pathological and therapeutic knowledge between the brain and the retina is transferrable. In addition, the investigation of glaucoma and AMD may be of significant therapeutic indication to AD brain. *AMD* age-related macular degeneration

The retina faithfully mirroring pathological events in the brain {#Sec17}
----------------------------------------------------------------

The neuronal cells in the retina belong to the CNS. When anti-Aβ antibody was injected into a transgenic mouse model, Aβ plaques were decreased in both the retina and the brain (Ding et al. [@CR22]). Another immunotherapy study demonstrated that APP~swe~/PS1~∆E9~ transgenic mice immunized with an altered myelin-derived peptide had a decrease of Aβ plaques in the retina and the brain to a similar extent (Koronyo-Hamaoui et al. [@CR53]). Since the anatomical structure of the retina is far much simple than that of the brain, one can use the retina to investigate the degenerative processes, signaling mechanisms, and even neuroprotective agents. For example, the retina has been used to investigate the neuroprotective effects of autoimmune responses (Bakalash et al. [@CR5]), which resemble the modulation of autoimmune responses to the brain so that beneficial effects can be observed. We have demonstrated that Stat3 pathway is involved in neurodegeneration after glaucoma (Ji et al. [@CR45]), which has also been recently demonstrated to be an important signaling pathway in AD (Wan et al. [@CR103]). Furthermore, synthesis of amyloid precursor protein and its intracellular transport have been investigated in the retina (Morin et al. [@CR68]; Stamer et al. [@CR94]). The retina provides a very simple model system for these authors to advance our understanding of APP synthesis and transport. All of these studies indicate that the retina can reliably represent amyloid plaque pathological events in the brain.

Simple and non-invasive imaging for the retina facilitates the monitoring of the progression of neurodegeneration {#Sec18}
-----------------------------------------------------------------------------------------------------------------

Recent advances of imaging technologies for the retina have given the opportunity for the development of a more definitive and non-invasive diagnostic tool for AD pathology (Hintersteiner et al. [@CR39]; Nakada et al. [@CR70]; Cordeiro et al. [@CR21]). Koronyo-Hamaoui et al. ([@CR53]) identified amyloid plaques in the retinas from AD patients as well as those suspected as early stage cases. It was confirmed that the retina can faithfully reflect AD brain pathology. The transparent nature of the eyes allows direct tracking and visualization of the progressive changes in amyloid pathology (Cordeiro et al. [@CR21]). The systemic injection of curcumin into live APP ~swe~/PS1~ΔE9~ mice allows a high-resolution and specific non-invasive visualization of retinal Aβ plaques in situ (Koronyo-Hamaoui et al. [@CR53]). Curcumin is a natural and safe fluorochrome that binds and labels Aβ plaques (Garcia-Alloza et al. [@CR29]; Yang et al. [@CR108]). In a 6-month randomized, placebo-controlled, double-blind, pilot clinical trial in AD patients, there were no significant side effects even when patients took curcumin at a dose of 4 g/day (Baum et al. [@CR6]). Future development of high-resolution optical imaging for early AD diagnosis, prognosis assessment, and response to therapies can be achieved non-invasively through direct imaging of the retina. Progression of therapy is possible to be visualized qualitatively in the sense that one can monitor the changes of a particular neuronal cell (Hintersteiner et al. [@CR39]; Nakada et al. [@CR70]). Quantitative examinations of the disease stages have been performed by assessing the ratio of apoptosis to necrosis using the fluorescence counts of the respective dyes (Cordeiro et al. [@CR21]). Even more, a high spatial resolution of images with a high signal-to-noise ratio ranging from 3:1 to 10:1 can be achieved with the imaging of the retina (Hintersteiner et al. [@CR39]; Nakada et al. [@CR70]). The merits of retinal imaging can provide investigators a solid support for assessing pathological status as well as developing and refining therapeutic strategies because the technique is less invasive and not sophisticated.

AD-related retinal degeneration advancing both the retinal degeneration and AD researches {#Sec19}
=========================================================================================

Knowledge being transferable between the brain and the retina {#Sec20}
-------------------------------------------------------------

Increasing lines of evidence highlight the commonalties shared between AD and retinal degeneration. In particular, Aβ deposits are found in the brain and the retina. As stated above, neuronal cell loss, inflammatory responses, and other pathological events that occurred in the retina are similar to those that occurred in the brain (Guo et al. [@CR36]). However, the correlation between Aβ deposits and the retina is limited to the histopathological level. The pathological mechanisms have not been investigated in great detail. Lots of questions are waiting for answers by more researches to be conducted. What is the correlation between Aβ depositions and inflammatory responses in the retina? How do Aβ deposits trigger apoptotic pathways in RGCs? What are other mechanisms taken by Aβ and tau to cause retinal degeneration? Although the relationship for Aβ production and toxicity between the brain and the retina remains unclear, the pathological pathways are possibly shared between the two to a certain extent. For example, mitochondrial dysfunctions and activation of complement, which will be discussed below, are pathophysiological changes in both AD and retinal degeneration (Kong et al. [@CR52]; Valenti [@CR100]). The similarity between the brain and the retina allows the exchange of knowledge in terms of pathological mechanisms and therapeutic intervention.

The discovery of the significant involvement of double-stranded RNA-dependent protein kinase (PKR) in the apoptosis of neurons in postmortem AD brain and in experimental studies is a good example (Chang et al. [@CR15], [@CR16]; Suen et al. [@CR95]). Having reported the involvement of PKR in neuronal apoptosis, it has been further found that PKR also plays important roles in the neuronal apoptosis of RGCs in endoplasmic reticulum (ER) stress-induced retinal neuronal loss (Shimazawa et al. [@CR92]). We have recently demonstrated that the neuroprotective agents found from AD research can also be applied to eye research. Our studies on wolfberry, *Lycium barbarum*, an anti-aging herb, can be a good example of sharing that knowledge obtained from studying the brain can be applied into the retina (Chan et al. [@CR14]). In AD, wolfberry can alleviate the degenerative process by promoting survival signals, suppressing ER stress, and reducing glutamate excitotoxicity (Yu et al. [@CR111]; Chan et al. [@CR14]; Yu et al. [@CR112]; Ho et al. [@CR40]; Ho et al. [@CR41], [@CR42]). In glaucoma, wolfberry shows its beneficial effects on the retina based on suppressing the neurodestructive factors, modulating the inflammatory responses (Chiu et al. [@CR19]), and induction of protective chaperone (Chiu et al. [@CR20]). The neuroprotective effects of wolfberry shared between AD and glaucoma further strengthen our hypothesis that knowledge obtained from the brain and the retina are transferrable.

AD-related retinal degeneration can help us in understanding retinal degeneration in other eye diseases {#Sec21}
-------------------------------------------------------------------------------------------------------

Based on the findings above that Aβ deposits were observed in the retinal layers of AD transgenic mice, studying AD-related retinal degeneration in the AD models may provide some implications on how Aβ deposits are linked to retinal degeneration. Two prominent examples of retinal degeneration associated with AD are glaucoma and AMD (Blanks et al. [@CR10]). In glaucoma, the presence of Aβ was observed in RGCs. In AMD, Aβ assemblies were accumulated in the form of drusen which are entrapped between the retinal epithelial layer and the Bruch's membrane (McKinnon [@CR62]; Anderson et al. [@CR3]). Therefore, it is reasonable to speculate that the accumulation of Aβ peptides (but not plaques) may contribute to retinal degeneration in these diseases.

### Aβ-mediated mitochondrial dysfunction and glaucoma {#Sec22}

Glaucoma is characterized by the progressive degeneration of RGCs induced by increased intraocular pressure (Yin et al. [@CR109]). However, signs of glaucoma are also elicited even after the reduction of IOP to normal level (Valenti [@CR100]). This clearly indicates that loss of RGCs can be neurodegenerative processes and various pathological events synergistically contribute to the pathogenesis of glaucoma. One of the triggers being proposed is Aβ-induced glaucoma. Indeed recent reports have demonstrated a potential link between glaucoma and AD. Patients who suffer from AD also show changes of the retina typically found in glaucoma (Guo et al. [@CR36]). At the molecular level, intracellular accumulation of Aβ was observed in RGCs. Accumulation of intracellular Aβ contributes to axonopathy and initiates apoptotic pathway in the brain (Ohyagi et al. [@CR76]; Suo et al. [@CR96]). The deleterious effects of intracellular Aβ in the brain may also be applied to the eye because intracellular Aβ exerts its toxicity to RGCs, reinforcing the degenerative process of the retina in addition to high IOP.

One of the pathological events in AD brain involves abnormal mitochondrial activities (Seo et al. [@CR91]). Mitochondria are dynamic organelles in which the balance between fission and fusion processes is important for maintaining their healthy functions (Wang et al. [@CR105]). Impairment of fission and fusion has been considered to be one of the pathophysiological indexes in AD (Santos et al. [@CR88]). There are some suggestions that Aβ peptides will modulate the cytosolic Ca^2+^ level in mitochondria that may alter the mitochondrial morphology and physiology (Hung et al. [@CR44]). For example, elevated cytosolic Ca^2+^ level may enhance the fragmentation of mitochondria and hence lead to the perturbation of fission and fusion balance which may eventually cause mitochondrial dysfunction (Saotome et al. [@CR89]). Dysregulation of Ca^2+^ homeostasis may also disrupt the downstream pathways of Ca^2+^-dependent regulators monitoring mitochondrial dynamics (Liu and Hajnoczky [@CR57]; Hung et al. [@CR44]). In particular, an abnormal distribution of mitochondrial fission and fusion proteins such as OPA1 and Fis1 may occur, and thus the distribution of mitochondria may be negatively affected in neurons (Wang et al. [@CR105]). Consequently, synaptic dysfunction may result due to the failure of meeting the energy demand in neurons, particularly in axonal and dendritic tips (Allen et al. [@CR1]; Liu and Hajnoczky [@CR57]; Wang et al. [@CR105]).

The eyes are energy-demanding organs where a lot of mitochondria accumulate, particularly at the optic nerve heads, to support the visual function of the eyes (Carelli et al. [@CR11]). Applying the same pathological mechanism to the eyes, Aβ present in RGCs may initiate similar pathways for mitochondrial dysfunctions, eventually leading to retinal degeneration. This hypothesis may be extended to one of the causes in Aβ-induced glaucoma. Intriguingly, in a glaucomatous model where cultured RGCs were subjected to elevated hydrostatic pressure, mitochondrial fission was found to be enhanced, together with morphological changes and bioenergetic dysfunction (Ju et al. [@CR48]). The approach of studying AD-related retinal degeneration is thus valuable for evaluating the pathogenesis of glaucoma.

### Aβ-mediated inflammation and AMD {#Sec23}

AMD is characterized by the progressive degeneration of retinal pigment epithelium and photoreceptor cells (Margrain et al. [@CR61]). Drusen as the hallmark of AMD has been reported to contain Aβ assemblies among various amounts of heterogeneous components (Luibl et al. [@CR59]). Hypothesis has been made for the linkage between AMD and AD because the similarity between two diseases is largely based on the complement activation induced by Aβ peptides. However, there is conflicting evidence on Aβ deposits in these two diseases at the ultrastructural level (Anderson et al. [@CR3]; Rodrigues [@CR85]). Inflammatory factors triggered by Aβ assembly initiates exudative AMD in which vascular endothelial growth factor (VEGF), being one of the main components of blood vessel growth, may be abnormally secreted (Yoshida et al. [@CR110]). The potential role of Aβ peptides in modulating angiogenesis may explain why AMD is related to AD because of the chronic inflammatory process. However, it should be noted that the key component of drusen contributing to AMD remains to be elucidated.

Recently, efforts have been put into the quest on how Aβ deposits take part in inflammation which is a key causative link to exudative AMD. The presence of Aβ aggregates was specific to AMD eyes (Anderson et al. [@CR2]) and a number of evidence showed the histopathological correlation between inflammation and Aβ aggregates. Aβ assemblies, which were detected in the degenerate RPE cells, may involve the formation of amyloid vesicle-containing drusen flanking RPE cells at the sub-RPE space (Johnson et al. [@CR47]). However, our understanding of how Aβ assemblies exactly activate complement cascade is still developing.

A hypothesis that Aβ contributes to inflammatory events along with the formation of drusen has been proposed (Anderson et al. [@CR3]). RPE cells are vulnerable to cell debris and other accumulated substances such as lipofuscin (Anderson et al. [@CR3]). The gradual built-up of cell debris may initiate the formation of drusen which encapsulates proteins, lipids, as well as inflammatory components (Anderson et al. [@CR2]). Thus, there is a possibility that the amyloid vesicles found in drusen may be made up of the extracellular Aβ deposits derived from the injured RPE cells. Similar to what can be found in AD where Aβ aggregates involve the activation of complement, Aβ deposition in the extracellular RPE matrix was suggested to be a primary activator of complement cascade in which the components responsible for the alternative activation pathway of the complement system were detected in AMD (Johnson et al. [@CR47]; Gold et al. [@CR32]). Cleavage of C3 component into C3a and C3b and subsequently cleavage of C5 component to trigger the formation of membrane attack complex (Anderson et al. [@CR2]) can be found in both AD and AMD.

Choroidal neovascularization is a pathological feature of exudative AMD in which VEGF-mediated angiopathy is a key pathophysiological process (Patel and Chan [@CR77]). Aβ may be associated with abnormal VEGF production triggered by impaired cells and a series of inflammatory events. For example, Roque and Caldwell ([@CR87]) have initially proposed that VEGF was produced by the impaired Müller cells, which was later supported by Pierce et al. ([@CR80]). Recently, Yoshida et al. ([@CR110]) suggested that Aβ assembly in drusen enhanced the release of VEGF and pigment epithelium-derived factor from RPE cells and promoted angiogenesis. Accumulation of cell debris in RPE was suggested to be a pro-inflammatory stimulation activating choroidal dendritic cells which subsequently recruit macrophages to enhance the production of VEGF (Zarbin [@CR114]). Other reports have proposed that VEGF was up-regulated by C3a and C5a (Nozaki et al. [@CR73]). Taking all these findings into consideration, Aβ peptides can activate the complement system in which C3a and C5a are potent stimuli of angiogenesis in AMD. Studying AD-related retinal degeneration is a valuable tool in evaluating complement activation and subsequent angiopathy in AMD.

AD-related retinal degeneration shows a therapeutic significance of early AD {#Sec24}
----------------------------------------------------------------------------

Early signs of AD symptoms in the brain can hardly be detected. In the most recent study of the APP~swe~/PS1~ΔE9~ mice, 5 days of systemic administration of curcumin showed that there was a qualitative age-dependent correlation between plaque deposition in the retina and the brain and increased accumulation over the course of disease progression (Koronyo-Hamaoui et al. [@CR53]). For the very first time, they proved that Aβ plaques in the retina precede brain plaques as early as 2.5 months of age in AD-Tg mice model. The first detectable Aβ plaques in the brain were at the age of 5 months which is consistent with previous studies in this line of AD-Tg mice (Garcia-Alloza et al. [@CR28]). Therefore, retinal degeneration is the most important site to study in early AD pathology. In APP~swe~/PS1~ΔE9~ mice, following MOG45D-loaded dendritic cells immunization, Aβ-plaque burden in the retinas was reduced as effectively as that in the brain (Koronyo-Hamaoui et al. [@CR53]). Considering the potentiation of direct optical imaging of the retina, especially the Aβ plaques deposition in the retina labeled by curcumin, retinal degeneration in early AD is the window of monitoring disease progression as well as effectiveness of treatment.

In the study where extracellular Aβ was injected into a glaucomatous model, immunotherapy with a potential agent such as β-secretase inhibitor, Congo Red, or Aβ antibody successfully reduced Aβ-induced RGC apoptosis by suppressing further Aβ aggregation and inhibiting the enzymatic activity of amyloidogenesis (Guo et al. [@CR35]). The effectiveness of each medication was also assessed by quantifying RGC apoptosis under the same dosage of each drug (Guo et al. [@CR35]). This study is a good example illustrating that the retina can be a promising platform to investigate the efficacy of any potential drugs on different neuronal cells. In addition to traditional delivery system, potential neuroprotective agents can be applied in the posterior chamber by intravitreous injection (Chiu et al. [@CR17]; Chiu et al. [@CR18]). The bioavailability of injected compound in the vitreous can be extended (Mey and Thanos [@CR65]). An examination of pharmacokinetic and pharmacodynamic is much easier than that in the brain. Changes in a particular layer may imply some effects of certain therapeutic agents on certain types of neuronal cells. For example, changes in INL may be an indication of some abnormalities that occurred in horizontal cells, amacrine cells, or bipolar cells. Taken together, the potent translation of treatment responses from the retina to the brain proves that studying AD-related retinal degeneration is of great therapeutic value in the early onset of AD.

Ocular disease models are beneficial to the investigation of AD pathogenesis {#Sec25}
============================================================================

On one hand, studying AD-related retinal degeneration can offer chances to elucidate the pathological processes induced by Aβ in the retina of glaucoma or AMD patient. On the other hand, each of the ocular disease models mimic glaucoma and AMD can help us to understand the pathogenesis of AD.

In glaucoma, previous studies have shown that intracellular Aβ is found in the glaucomatous models (McKinnon et al. [@CR63]). This may provide an excellent experimental model because both extra- and intracellular Aβ peptides contribute to the pathogenesis of AD. The accumulation of intracellular Aβ peptides has been shown to be neurotoxic in the brain (LaFerla et al. [@CR54]; Li et al. [@CR56]). This indicates that a glaucomatous model can provide hints on the pathological mechanisms of intracellular Aβ peptides.

In terms of AMD, Aβ assembly in drusen is non-fibrillar peptides or oligomers instead of fibrillar plaques observed in AD (Luibl et al. [@CR59]). Recent studies have demonstrated that Aβ oligomers are neurotoxic because they disrupt dendritic spines and depress synaptic signaling which lead to cognitive deficits (Allen et al. [@CR1]; Walsh et al. [@CR101], [@CR102]; Wang et al. [@CR104]; Nimmrich et al. [@CR71]). Studying AMD models can possibly provide suggestions on how Aβ oligomers lead to AD pathogenesis.

Conclusion {#Sec26}
==========

Brain research in AD has been widely conducted, while the retinal investigation in AD is a new arena to be explored. The interchangeable knowledge between the brain and the retina allows the concepts of Aβ pathology in the AD retina to be borrowed from those in the AD brain. Research in the retina offers many advantages over the brain in terms of cost, time, and analytical methods. Research in the AD retina resembles the pathological changes in AD brain. Therefore, studying AD-related retinal degeneration will be beneficial in assessing AD pathological changes and developing new AD therapeutic treatments in a simple and effective manner. Complementarily by AD transgenic models, the investigation of AD-related retinal degeneration may introduce a new channel to study AD in a different perspective (Fig. [2](#Fig2){ref-type="fig"}).
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